



Giannini F, Sabatelli M, IMC Trial Group. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. *Lancet Neurol* 2012; 11: 493–502.

**13.** Pourmand R. Immune-mediated neuromuscular diseases. Basel: Karger, 2009.

**14.** Rabin M, Mutlu G, Stojkovic T, Maisonobe T, Lenglet T, Fournier E, Bouche P, Leger JM, Viala K. Chronic inflammatory demyelinating polyradiculoneuropathy: search for factor associated with treatment dependence or successful withdrawal. *J Neurol Neurosurg Psychiatry* 2014; 85: 899–904.

**15.** Sommer C. Therapie akuter und chronischer immunvermittelter Neuropathien und Neuritiden. Deutsche Gesellschaft für Neurologie. Leitlinien für Diagnostik und Therapie

in der Neurologie Aufl. 5, 2012. [www.dgn.org](http://www.dgn.org)

**16.** Vallat JM, Sommer C, Magy L. Chronic demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. *Lancet Neurol* 2010; 9: 402–412.

**17.** Van Schaik IN, Eftimov F, van Doorn PE. Pulsed high dose dexamethasone treatment versus standard prednisolone treatment in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): a double blind randomized controlled clinical trial (PREDICT study). *Lancet Neurol* 2010; 9: 245–253.

**18.** Yoon MS, Chan A, Gold R. Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy. *Ther Adv Neurol Disor* 2011; 4: 193–200.